Jonathan Schott is a Professor of Neurology at UCL with particular expertise in dementia and Alzheimer's disease, and Chief Medical Officer for Alzheimer's Research UK.
Being able to identify Alzheimer’s disease from a blood test might sound like science fiction, but thanks to the Blood Biomarker Challenge funded by Alzheimer’s Research UK, Alzheimer’s Society and players of the People’s Postcode Lottery it could be a reality in as little as five years.
At UCL Professor Jonathan Schott and Dr Ashvini Keshavan (both UCL Queen Square Institute of Neurology), are heading up the ‘ADAPT’ team investigating the most promising biomarker for Alzheimer’s disease, called p-tau217, part of the Blood Biomarker Challenge.
Elevated levels of p-tau217 in the blood or cerebrospinal fluid indicate the presence of two hallmarks of Alzheimer’s disease – amyloid plaques and tangles containing tau within the brain
The ADAPT team will be carrying out a clinical trial in NHS memory clinics across the UK to see whether measuring p-tau217 in the blood increases the rate of diagnosis for Alzheimer’s disease both in people with early dementia, and those with mild, progressive problems with memory.
It is their hope that this research will establish this blood test as a routine means of helping diagnose Alzheimer’s disease, allowing early detection and intervention when new treatments become available. In this video, Professor Schott talks about the ADAPT study and how blood tests for Alzheimer’s disease may be just around the corner.
In this video, Professor Schott talks about what motivates him to research Alzheimer’s disease and how collaboration is key when it comes to dementia research.
Links:
- Blood tests for diagnosing dementia to be offered in UK trial
- Professor Jonathan Schott's academic profile
- An article on Insight 46, published in The Conversation
- Read more about the work, and the team, behind Insight 46